Literature DB >> 20584582

Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques.

David A Palma1, Suresh Senan, Cornelis J A Haasbeek, Wilko F A R Verbakel, Andrew Vincent, Frank Lagerwaard.   

Abstract

PURPOSE: Lung fibrosis is common after stereotactic body radiotherapy (SBRT) for lung tumors, but the influence of treatment technique on rates of clinical and radiological pneumonitis is not well described. After implementing volumetric modulated arc therapy (RapidArc [RA]; Varian Medical Systems, Palo Alto, CA) for SBRT, we scored the early pulmonary changes seen with arc and conventional three-dimensional SBRT (3D-CRT). METHODS AND MATERIALS: Twenty-five SBRT patients treated with RA were matched 1:2 with 50 SBRT patients treated with 3D-CRT. Dose fractionations were based on a risk-adapted strategy. Clinical pneumonitis was scored using Common Terminology Criteria for Adverse Events version 3.0. Acute radiological changes 3 months posttreatment were scored by three blinded observers. Relationships among treatment type, baseline factors, and outcomes were assessed using Spearman's correlation, Cochran-Mantel-Haenszel tests, and logistic regression.
RESULTS: The RA and 3D-CRT groups were well matched. Forty-three patients (57%) had radiological pneumonitis 3 months after treatment. Twenty-eight patients (37%) had computed tomography (CT) findings of patchy or diffuse consolidation, and 15 patients (20%) had ground-glass opacities only. Clinical pneumonitis was uncommon, and no differences were seen between 3D-CRT vs. RA patients in rates of grade 2/3 clinical pneumonitis (6% vs. 4%, respectively; p = 0.99), moderate/severe radiological changes (24% vs. 36%, respectively, p = 0.28), or patterns of CT changes (p = 0.47). Radiological severity scores were associated with larger planning target volumes (p = 0.09) and extended fractionation (p = 0.03).
CONCLUSIONS: Radiological changes after lung SBRT are common with both approaches, but no differences in early clinical or radiological findings were observed after RA. Longer follow-up will be required to exclude late changes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20584582     DOI: 10.1016/j.ijrobp.2010.02.032

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  26 in total

Review 1.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

2.  Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC.

Authors:  S Arcangeli; L Agolli; L Portalone; M R Migliorino; M G Lopergolo; A Monaco; J Dognini; M C Pressello; S Bracci; V Donato
Journal:  Br J Radiol       Date:  2015-02-03       Impact factor: 3.039

Review 3.  Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

Authors:  Sarah A Mattonen; Aaron D Ward; David A Palma
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

Review 4.  Improving radiotherapy planning, delivery accuracy, and normal tissue sparing using cutting edge technologies.

Authors:  Carri K Glide-Hurst; Indrin J Chetty
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

5.  Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomy.

Authors:  Christoph Pöttgen; Jehad Abu Jawad; Eleni Gkika; Lutz Freitag; Wolfgang Lübcke; Stefan Welter; Thomas Gauler; Martin Schuler; Wilfried Ernst Erich Eberhardt; Georgios Stamatis; Martin Stuschke
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

6.  The mean lung dose (MLD) : predictive criterion for lung damage?

Authors:  Thomas Herrmann; Peter Geyer; Steffen Appold
Journal:  Strahlenther Onkol       Date:  2015-04-13       Impact factor: 3.621

7.  No differences in radiological changes after 3D conformal vs VMAT-based stereotactic radiotherapy for early stage non-small cell lung cancer.

Authors:  Serena Badellino; Jacopo Di Muzio; Giulia Schivazappa; Alessia Guarneri; Riccardo Ragona; Sara Bartoncini; Elisabetta Trino; Andrea Riccardo Filippi; Paolo Fonio; Umberto Ricardi
Journal:  Br J Radiol       Date:  2017-09-04       Impact factor: 3.039

8.  Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.

Authors:  Grit S Herter-Sprie; Shohei Koyama; Houari Korideck; Josephine Hai; Jiehui Deng; Yvonne Y Li; Kevin A Buczkowski; Aaron K Grant; Soumya Ullas; Kevin Rhee; Jillian D Cavanaugh; Neermala Poudel Neupane; Camilla L Christensen; Jan M Herter; G Mike Makrigiorgos; F Stephen Hodi; Gordon J Freeman; Glenn Dranoff; Peter S Hammerman; Alec C Kimmelman; Kwok-Kin Wong
Journal:  JCI Insight       Date:  2016-06-16

Review 9.  Pathologic response after modern radiotherapy for non-small cell lung cancer.

Authors:  Simon F Roy; Alexander V Louie; Moishe Liberman; Philip Wong; Houda Bahig
Journal:  Transl Lung Cancer Res       Date:  2019-09

10.  Lung stereotactic body radiotherapy using a coplanar versus a non-coplanar beam technique: a comparison of clinical outcomes.

Authors:  Christopher L Hallemeier; Michael C Stauder; Robert C Miller; Yolanda I Garces; Robert L Foote; Jann N Sarkaria; Heather J Bauer; Charles S Mayo; Kenneth R Olivier
Journal:  J Radiosurg SBRT       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.